About Werewolf
Werewolf is a publicly listed company based in Cambridge (United States) founded in 2017 by Dan Hicklin. Developer of Immuno-stimulation medicines therapy for cancer therapy. Werewolf has raised $128.24 million across 3 funding rounds from investors including RA Capital, HBM Healthcare Investments and Deerfield. The company has 46 employees. Its chief executive, as recorded, is Dan Hicklin. Werewolf offers products and services including INDUKINE Molecules and PREDATOR Technology. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Werewolf Therapeutics Inc. Its competitors include Revolution Medicines, Blueprint Medicines and Syndax; 3 of its 3 listed competitors have raised funding.
Company details
Werewolf is the developer of Immuno-stimulation medicines therapy for cancer therapy. The platform has developed the proprietary technology PREDATOR through protein engineering approach. Its proinflammatory cytokines and costimulatory multivalent receptor agonists target the specifically for the cancer cells.
- Headquarters Cambridge, United States
- Employees 46
- Founders Dan Hicklin
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website werewolftx.com
- Social LinkedIn X
- Legal Name Werewolf Therapeutics, Inc.
- Net Profit-$60.82 M (USD)13.75as on Dec 31, 2025
- EBITDA-$59.04 M (USD)17.74as on Dec 31, 2025
- Total Equity Funding$128.24M (USD)
in 3 rounds
- Latest Funding Round$150M (USD), Post-IPO
Aug 2026
- InvestorsRA Capital
& 13 more
- Employee Count46
Products & Services of Werewolf
Werewolf offers a comprehensive portfolio of products and services, including INDUKINE Molecules and PREDATOR Technology.
Systemically administered therapies that activate in tumor environments to boost immune responses.
Platform for designing and engineering immuno-oncology biotherapeutics for cancer treatment.
Funding Insights of Werewolf
Werewolf has successfully raised a total of $128.24M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $150 million completed in August 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $128.24M
- Total Rounds 3
- Last Round Post-IPO — $150M
- First Round $56.17M
(Aug 2020)
- Investors Count 14
All 3 funding rounds of Werewolf with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2026 | $150M | Post-IPO | – | RA Capital Management, Janus Henderson Investors | – |
| Jan 2021 | $72.07M | Series B | – | RA Capital Management | |
| Aug 2020 | $56.17M | Series A | – | MPM Capital, Longwood Fund |
14 investors in total: 14 institutional.
Investors in Werewolf
Werewolf has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include RA Capital, HBM Healthcare Investments and Deerfield.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
| soleuscapital.com | ||||
Venture capital fund investing in early & growth-stage companies | dcinvestmentpartners.com | Mclean, United States | ||
Venture capital is directed toward healthcare companies by Longwood Fund. | longwoodfund.com | Boston, United States | ||
| arkinholdings.com | ||||
Taiho Ventures is focused on investing in global biotech ventures. | 2016 | taihoventures.com | Menlo Park, United States | |
| janushenderson.com | ||||
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Offers investment management and secure information access to clients and partners. | 2001 | adagecapital.com | Boston, United States |
Investor details for Werewolf
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Werewolf
36 people are tracked at Werewolf (17 in leadership, 11 in board & advisors, 8 in team); the tracked headcount is 46.
| Name | Role | Group |
|---|---|---|
Dan Hicklin | Founder & CEO | Leadership |
Michael U. | Corporate Controller, Vice President Of Finance | Leadership |
Chulani Karunatilake | CTO | Leadership |
Randi Isaacs | CMO | Leadership |
Tim Trost | CFO | Leadership |
Andres Salmeron | VP, Immunology | Leadership |
Christopher J. Nirschl | Director, Immunology | Leadership |
Michael Trencher | Vice President, Financial Planning And Analysis | Leadership |
Kulandayan Subramanian | Head Of Clinical Pharmacology And Pharmacometrics | Leadership |
Karen Fiello | Vp, People Operations | Leadership |
Heather Brodkin | Vp, Protein Engineering | Leadership |
Rebecca Cavallaro | Executive Assistant To Chief Executive Officer | Leadership |
Nancy Weil | VP Program And Portfolio Management | Leadership |
Sameer S. Chopra | Vice President, Clinical Development | Leadership |
William Winston | VP, Research | Leadership |
Kara Malcolm | Senior Director, Clinical Scientist | Leadership |
Saero Park | Executive Director, Clinical Operations | Leadership |
Vijay K. Kuchroo | Scientific Advisor | Board & advisors |
Alon Lazarus | Director | Board & advisors |
Briggs W. Morrison | Director | Board & advisors |
16 more people are available in the full profile.
Complete people profiles for Werewolf
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Werewolf
Werewolf is a publicly listed company on the NASDAQ with ticker symbol HOWL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date30 Apr 2021
- Listed onNASDAQ: HOWL
- Listed entityWerewolf Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS95075A1079
- Share price$0.99 (+0.95% on the day) · 2026-10-13
- Market capitalisation$48.2M
- EPS (diluted, trailing year)$-0.74
- Volume (last session)355,187
Financials of Werewolf
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$60.8M | -$59.0M | |
| 2024 | $1.9M | -$70.5M | -$71.8M |
| 2023 | $19.9M | -$37.4M | -$38.7M |
| 2022 | $16.4M | -$53.8M | -$53.5M |
| 2021 | -$50.0M | -$49.4M |
Detailed financial statements for Werewolf
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Werewolf
4 dated milestones of Werewolf across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Werewolf is founded.
- Funding First funding round of $56.2M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $150.0M.
Competitors of Werewolf
Werewolf has 3 listed competitors in our database, 3 of them funded. They include Revolution Medicines, Blueprint Medicines and Syndax.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. |
Detailed competitors of Werewolf
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Werewolf
The website of Werewolf (werewolftx.com) receives about 4.5K visits a month.
- Monthly visits4.5K
▼ 24% vs previous month
Websites whose visitors overlap most with Werewolf. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cuebiopharma.com | 100% | 4.9K | #7,063,180 | View details | |
| fluentbio.com | 99% | 4.7K | #3,913,179 | View details | |
| triveni.bio | 98% | 5.4K | #3,407,762 | View details | |
reintx.com | reintx.com | 95% | #3,977,411 | – | |
| sherlock.bio | 94% | 2.8K | #4,929,420 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Werewolf
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Werewolf (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Werewolf
Complete news archive for Werewolf
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Werewolf
Werewolf was founded in 2017 and raised its 1st funding round 3 years after it was founded.
Werewolf is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Dan Hicklin is the CEO of Werewolf, as recorded in our data. They have also founded this company.
Werewolf is a funded company, having raised a total of $128.24M across 3 funding rounds to date. The company's 1st funding round was a Series A of $56.17M, raised on Aug 2020.
Werewolf has 46 employees.
Werewolf is the developer of Immuno-stimulation medicines therapy for cancer therapy. The platform has developed the proprietary technology PREDATOR through protein engineering approach. Its proinflammatory cytokines and costimulatory multivalent receptor agonists target the specifically for the cancer cells.
Werewolf's top competitors include Syndax, Revolution Medicines and Blueprint Medicines.
Werewolf offers INDUKINE Molecules and PREDATOR Technology.
Yes, Werewolf is publicly traded on NASDAQ under the ticker symbol HOWL.
Werewolf has 14 investors. Key investors include RA Capital, HBM Healthcare Investments, Deerfield, Adage Capital Management, and Soleus Capital.
Werewolf operates through Werewolf Therapeutics Inc..